{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:22:41Z","timestamp":1792110161962,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13555-025-01458-3","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T03:08:45Z","timestamp":1750129725000},"page":"2147-2158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Diffusion Characteristics of LetibotulinumtoxinA, OnabotulinumtoxinA, and AbobotulinumtoxinA and its Impact on Muscle Relaxation: A Randomized Split-Face Clinical Trial"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1015-630X","authenticated-orcid":false,"given":"Maxine","family":"Bennek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rudowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kerscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"1458_CR1","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0190-9622(96)90016-X","volume":"34","author":"AKK Carruthers","year":"1996","unstructured":"Carruthers AKK, Carruthers J. Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol. 1996;34:788\u201397.","journal-title":"J Am Acad Dermatol"},{"key":"1458_CR2","doi-asserted-by":"publisher","first-page":"413e","DOI":"10.1097\/PRS.0b013e318170813c","volume":"121","author":"ACA Klein","year":"2008","unstructured":"Klein ACA, Fagien S, Lowe NJ. Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg. 2008;121:413e-e422.","journal-title":"Plast Reconstr Surg"},{"key":"1458_CR3","unstructured":"Surgery ISoAP. International survey on aesthetic\/cosmetic procedures. 2021."},{"issue":"3","key":"1458_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2174\/157488606777934431","volume":"1","author":"AM Bakheit","year":"2006","unstructured":"Bakheit AM. The possible adverse effects of intramuscular botulinum toxin injections and their management. Curr Drug Saf. 2006;1(3):271\u20139.","journal-title":"Curr Drug Saf"},{"issue":"3","key":"1458_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/14764170802094282","volume":"10","author":"A Pickett","year":"2008","unstructured":"Pickett A, Dodd S, Rzany B. Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther. 2008;10(3):181\u20133.","journal-title":"J Cosmet Laser Ther"},{"issue":"6","key":"1458_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/asj\/sjac019","volume":"42","author":"DS Mueller","year":"2022","unstructured":"Mueller DS, Prinz V, Adelglass J, Cox SE, Gold MH, Kaufman-Janette J, et\u00a0al. Efficacy and safety of letibotulinumtoxin A in the treatment of glabellar lines: a randomized, double-blind, multicenter, placebo-controlled phase 3 study. Aesthet Surg J. 2022;42(6):677\u201388.","journal-title":"Aesthet Surg J"},{"key":"1458_CR7","unstructured":"Gerd Gauglitz MI, Maurizio Podda, Benedicta Beck-Broichsitter, Holger Gassner, Olaf Kauder, Lutz Kleinschmidt, Julia Vent, Boris Sommer. S1-Leitlinie: \u00c4sthetische Botulinumtoxin-Therapie. AWMF-Register-Nr.: 013\u2013077, 202 2022."},{"issue":"12","key":"1458_CR8","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1111\/jdv.12408","volume":"28","author":"BJ Kim","year":"2014","unstructured":"Kim BJ, Kwon HH, Park SY, Min SU, Yoon JY, Park YM, et\u00a0al. Double-blind, randomized non-inferiority trial of a novel botulinum toxin A processed from the strain CBFC26, compared with onabotulinumtoxin A in the treatment of glabellar lines. J Eur Acad Dermatol Venereol. 2014;28(12):1761\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1458_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000002627","volume":"8","author":"JY Park","year":"2020","unstructured":"Park JY, Sunga O, Wanitphakdeedecha R, Frevert J. Neurotoxin impurities: a review of threats to efficacy. Plast Reconstr Surg Glob Open. 2020;8(1): e2627.","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"1458_CR10","first-page":"227","volume":"8","author":"MF Brin","year":"2014","unstructured":"Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014;8:227\u201341.","journal-title":"Biologics"},{"key":"1458_CR11","doi-asserted-by":"crossref","unstructured":"Philipp-Dormston WG. [Botulinum toxin in dermatology]. Hautarzt. 2014;65(2):133\u201343; quiz 44\u20135.","DOI":"10.1007\/s00105-013-2744-5"},{"issue":"2","key":"1458_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/mdc3.12235","volume":"3","author":"K Dashtipour","year":"2016","unstructured":"Dashtipour K, Chen JJ, Espay AJ, Mari Z, Ondo W. OnabotulinumtoxinA and abobotulinumtoxinA dose conversion: a systematic literature review. Mov Disord Clin Pract. 2016;3(2):109\u201315.","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"1458_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/mds.26085","volume":"30","author":"JY Yun","year":"2015","unstructured":"Yun JY, Kim JW, Kim HT, Chung SJ, Kim JM, Cho JW, et\u00a0al. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. Mov Disord. 2015;30(2):206\u201313.","journal-title":"Mov Disord"},{"issue":"1","key":"1458_CR14","first-page":"1","volume":"35","author":"S Karsai","year":"2009","unstructured":"Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg. 2009;35(1):1\u20138.","journal-title":"Dermatol Surg"},{"key":"1458_CR15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/BF01652699","volume":"101","author":"V Minor","year":"1928","unstructured":"Minor V. Ein neues Verfahren zu der klinischen Untersuchung der Schwei\u00dfbabsonderung. Dtsch Z Nervenheilkd. 1928;101:302\u20138.","journal-title":"Dtsch Z Nervenheilkd"},{"issue":"1","key":"1458_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1524-4725.2009.01364.x","volume":"36","author":"D Hexsel","year":"2010","unstructured":"Hexsel D, Rodrigues TC, Soirefmann M, Zechmeister-Prado D. Recommendations for performing and evaluating the results of the minor test according to a sweating intensity visual scale. Dermatol Surg. 2010;36(1):120\u20132.","journal-title":"Dermatol Surg"},{"key":"1458_CR17","doi-asserted-by":"crossref","unstructured":"Kerscher M, Maack M, Reuther T, Kr\u00fcger N. Diffusion characteristics of two different neurotoxins in patients with symmetric forehead lines. J Am Academy Dermatol. 2007; 56(2):Ab199-Ab.","DOI":"10.1016\/j.jaad.2006.10.906"},{"issue":"9","key":"1458_CR18","doi-asserted-by":"publisher","first-page":"e5287","DOI":"10.1097\/GOX.0000000000005287","volume":"11","author":"T Lim","year":"2023","unstructured":"Lim T, Kerscher M, Ogilvie A, Pavicic T, Lorenc PZ, Frank K, et\u00a0al. Novel validated five-point photonumeric scales for assessment of static and dynamic forehead lines. Plastic Reconstr Surg Global Open. 2023;11(9):e5287.","journal-title":"Plastic Reconstr Surg Global Open"},{"issue":"1","key":"1458_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000005525","volume":"12","author":"Y Xie","year":"2024","unstructured":"Xie Y, Yang X, Liang H, Bo H, Lu J, Guo Q, et\u00a0al. A phase-III noninferiority, randomized controlled trial of letibotulinum toxin A for the improvement of moderate-to-severe glabellar wrinkles in China. Plast Reconstr Surg Glob Open. 2024;12(1): e5525.","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"12","key":"1458_CR20","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1007\/s00415-008-0031-7","volume":"255","author":"K Wohlfarth","year":"2008","unstructured":"Wohlfarth K, Schwandt I, Wegner F, J\u00fcrgens T, Gelbrich G, Wagner A, et\u00a0al. Biological activity of two botulinum toxin type A complexes (Dysport\u00ae and Botox\u00ae) in volunteers. J Neurol. 2008;255(12):1932\u20139.","journal-title":"J Neurol"},{"key":"1458_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1524-4725.2006.32330.x","volume":"33","author":"AR Trindade de Almeida","year":"2007","unstructured":"Trindade de Almeida AR, Marques E, de Almeida J, Cunha T, Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007;33:37\u201343.","journal-title":"Dermatol Surg"},{"issue":"5","key":"1458_CR22","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/PRS.0000000000006756","volume":"145","author":"S Cotofana","year":"2020","unstructured":"Cotofana S, Freytag DL, Frank K, Sattler S, Landau M, Pavicic T, et\u00a0al. The bidirectional movement of the frontalis muscle: introducing the line of convergence and its potential clinical relevance. Plast Reconstr Surg. 2020;145(5):1155\u201362.","journal-title":"Plast Reconstr Surg"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01458-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01458-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01458-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:16:56Z","timestamp":1757189816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01458-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1458"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01458-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maxine Bennek reports no conflicts of interest. Daniela Rudowitz is employed by Croma-Pharma GmbH. Martina Kerscher has served as a speaker and\/or advisory board member for AbbVie\/Allergan, Merz Aesthetics, Croma-Pharma GmbH, Ipsen, Neauvia, Galderma, and Nordberg Medical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study (EU CT: 2024-511047-26-01) was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines. The research protocol was reviewed and approved by the Ethics Committee of the Medical Association of Munich (Ethikkommission bei der Medizinischen Fakult\u00e4t der Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Pettenkoferstra\u00dfe 8, M\u00fcnchen). All participants provided written informed consent to participate in the study. Consent for publication was obtained from all participants for whom identifiable data are included. All participants provided written informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}